HIMS Shares Decline Amid Lower Revenue Per Order For GLP-1 Following Novo Nordisk Collaboration Termination, Securities Class Action Pending — Hagens Berman
(NYSE:HIMS), SAN FRANCISCO, Aug. 08, 2025 (GLOBE NEWSWIRE) — On August 5, 2025, investors in Hims & Hers Health (NYSE: HIMS) declined almost 11% in another sell-off after the company disclosed that it would lower revenue recognized per customer specific to its so-called personalized GLP-1 component, a medication the company compounds to treat weight loss. […]